Research Paper Advance Articles

Figure 2. Changes in self-reported survey scores of quality of life and health. Females using 10 mg of rapamycin again had significant improvements in self-reported measures of pain at both 24 and 48 weeks (24 weeks: md = 6.765 (95% CI = 1.315–12.215), p = 0.011; 48 weeks: md = 8.071 (95% CI = 3.044–13.098), p < 0.001) (A). Additionally, improvements in measures of General Health reports were specific to the 5mg rapamycin group, increasing at 24 weeks and remaining relatively constant thereafter (24 weeks: md = 5.882 (95% CI = 0.388–11.376), p = 0.033; 48 weeks: md = 5.882 (95% CI = 1.350–10.415), p = 0.007) (B), however, improvements in Emotional Well-being were only seen for 5mg rapamycin users and placebo groups after 48 weeks (5mg: md = 5.176 (95% CI = 0.056–10.297), p = 0.047; placebo: md = 4.267 (95% CI = 0.432–8.102), p = 0.025) (C). md = mean difference, ^*=p ≤ 0.05, ^**p ≤ 0.01. Error bars represent standard error of the mean.